Planchard, DavidDavidPlanchardJänne, Pasi APasi AJänneCheng, YingYingChengCHIH-HSIN YANGYanagitani, NorikoNorikoYanagitaniKim, Sang-WeSang-WeKimSugawara, ShunichiShunichiSugawaraYu, YanYanYuFAN YUNGeater, Sarayut LSarayut LGeaterLaktionov, KonstantinKonstantinLaktionovLee, Chee KChee KLeeValdiviezo, NataliaNataliaValdiviezoAhmed, SamreenSamreenAhmedMaurel, Jean-MarcJean-MarcMaurelAndrasina, IgorIgorAndrasinaGoldman, JonathanJonathanGoldmanGhiorghiu, DanaDanaGhiorghiuRukazenkov, YuriYuriRukazenkovTodd, AlexAlexToddKobayashi, KunihikoKunihikoKobayashi2023-12-142023-12-142023-11-230028-47931533-4406https://scholars.lib.ntu.edu.tw/handle/123456789/637870Osimertinib is a third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) that is selective for EGFR-TKI-sensitizing and EGFR T790M resistance mutations. Evidence suggests that the addition of chemotherapy may extend the benefits of EGFR-TKI therapy.en[SDGs]SDG3journal article10.1056/NEJMoa2306434379377632-s2.0-85177794021https://api.elsevier.com/content/abstract/scopus_id/85177794021